December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Vitreous Levels of Hepatocyte Growth Factor Level and Transforming Growth Factor-ß2 in Patients With Proliferative Vitreoretinopathy
Author Affiliations & Notes
  • HS Ying
    Ophthalmology
    Doheny Eye Institute Keck School of Medicine at the University of Southern California Los Angeles CA
  • C Spee
    Ophthalmology
    Doheny Eye Institute Keck School of Medicine at the University of Southern California Los Angeles CA
  • JI Lim
    Ophthalmology
    Doheny Eye Institute Keck School of Medicine at the University of Southern California Los Angeles CA
  • SJ Ryan
    Ophthalmology
    Doheny Eye Institute Keck School of Medicine at the University of Southern California Los Angeles CA
  • DR Hinton
    Ophthalmology and Pathology
    Doheny Eye Institute Keck School of Medicine at the University of Southern California Los Angeles CA
  • Footnotes
    Commercial Relationships   H.S. Ying, None; C. Spee, None; J.I. Lim, None; S.J. Ryan, None; D.R. Hinton, None. Grant Identification: Support: NIH Grant EYO2061, NIH Grant EYO3040, and Research to Prevent Blindness.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 623. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      HS Ying, C Spee, JI Lim, SJ Ryan, DR Hinton; Vitreous Levels of Hepatocyte Growth Factor Level and Transforming Growth Factor-ß2 in Patients With Proliferative Vitreoretinopathy . Invest. Ophthalmol. Vis. Sci. 2002;43(13):623.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To determine whether the levels of hepatocyte growth factor (HGF) and transforming growth factor-ß2(TGF-ß2) are elevated in the vitreous of patients with proliferative vitreoretinopathy (PVR) compared to vitreous samples obtained from patients with other disorders. Methods: Undiluted core vitreous samples, removed during standard pars plana vitrectomy, were obtained from 5 eyes with PVR, 8 eyes with retinal detachment (RD), 6 eyes with macular hole (MH), and 4 eyes with epiretinal membrane (ERM). All patients were non-diabetic. Samples were immediately aliquoted and stored at -70ºC until analysis. HGF and TGF-ß2 levels in the vitreous were determined by quantitative enzyme-linked immunosorbent assay (R & D Systems). Results: HGF levels were elevated in the PVR group (42.1±14.3 ng/ml) vs. RD (9.00±1.57 ng/ml) or MH (7.51±0.92 ng/ml) or ERM (6.23±1.47 ng/ml; one-way ANOVA, P<0.05). TGF-ß2 levels followed a similar trend with highest levels in the PVR group (4.15±1.69 ng/ml) and lower levels in the RD (3.18±0.55 ng/ml), MH (2.38±0.30 ng/ml) and ERM (2.10±0.34 ng/ml; one-way ANOVA, P=0.268) groups. In several cases, the HGF and TGF-ß2 levels in individual vitreous samples did not correlate; however, each PVR case demonstrated high HGF and/or high TGF-ß2 levels. Conclusion: These data confirm the observation that HGF levels are elevated in the vitreous of PVR patients. The poor correlation of HGF and TGF-ß2 levels in the vitreous from individual patients with PVR is consistent with the hypothesis that HGF and TGF-ß2 are differentially activated in the pathogenesis of PVR.

Keywords: 524 proliferative vitreoretinopathy • 358 clinical laboratory testing • 423 growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×